Navigation Links
New Research Uncovers Elusive Target of Antifungal Agent
Date:6/13/2010

A research team in Japan has uncovered the mechanism underlying the antifungal activity of theonellamide (TNM), a bioactive compound found in a species of marine sponge. The finding, reported in Nature Chemical Biology, provides new insights toward the development of antifungal drugs, with broader applications to drug analysis in areas such as cancer research.

(PRWeb UK) June 13, 2010 -- A research team in Japan has uncovered the mechanism underlying the antifungal activity of theonellamide (TNM), a bioactive compound found in a species of marine sponge. The finding, reported in Nature Chemical Biology, provides new insights toward the development of antifungal drugs, with broader applications to drug analysis in areas such as cancer research.

Designing drugs that target fungal cells poses serious challenges due to their similarity to human cells at the molecular level. To avoid damaging human cells, such drugs exploit differences between mammalian and fungal cells, both of which, unlike bacteria, are in the same family of eukaryotes. The difficulty of this task results in toxic side effects and a shortage of effective antifungal agents.

The research team, headed by scientists at the RIKEN Advanced Science Institute, set out to tackle this problem by investigating the antifungal activity of theonellamides (TNMs), bicyclic peptides found in the marine sponge Theonella, on the fission yeast. Combining chemical-genetic profiling and biochemical and cellular analysis, they deduced that TNMs bind to a class of lipid molecules (3?-hydroxysterols) in the cell membrane to induce overproduction of 1,3-?-D-glucan, a component of the cell wall.

Antifungal activity in TNMs, the researchers showed, is thus different from other antifungals, which cause damage by impairing wall synthesis. Instead, TNMs damage fungal cells by abnormally promoting such synthesis, targeting not proteins as previously thought, but a class of lipids, including ergosterol. TNMs thus represent an entirely new class of sterol-binding molecules, offering a new direction in the development of antifungal agents and a powerful tool for drug analysis.

For more information, please contact:

Dr. Minoru Yoshida
Chemical Genomics Research Group
RIKEN Advanced Science Institute
Tel: +81-(0)48-467-9516 / Fax: +81-(0)48-467-4676

Ms. Tomoko Ikawa (PI officer)
Global Relations Office
RIKEN
Tel: +81-(0)48-462-1225 / Fax: +81-(0)48-462-4715

# # #

Read the full story at http://www.prweb.com/releases/2010/06/prweb4131144.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. New research identifies modifiable risk factors for heart disease
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Researcher to track spread of disease, malware and power outages
4. UCSF Researchers Identify Regulator of Human Sperm Cells
5. Octapharma Accepting Applications for Research Grants Through March 31
6. Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. University of Maryland chemist receives Astellas Award for blindness prevention research
9. Developing a cyberinfrastructure for comparative effectiveness in cancer research
10. Women should be allowed to eat, drink during labor: Queens University researcher
11. Parkinsons disease research uncovers social barrier
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Research Uncovers Elusive Target of Antifungal Agent
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology: